FENG 05.01-IP.01-007/26 – Ścieżka B: Projekty realizowane w sektorze biotechnologie

Applicant types

SME, Large company, Research org, NGO

Purpose

Research and innovation

R&D relevance

3 of 3

Poland eligible

Yes

Country limit

Poland

Region

Any

Consortium

Optional

Readiness level (TRL)

—

Per project

€33M

Topics

• Critical biotechnology
• Critical medicines
• Medicine components

Machine-classified from the call text; check eligibility at the source. 23 Oct 2026

Typed facts extracted from the source documents by Scindu's grant-data review. Each value keeps its own conditions. Unknown means unstated, not zero or unlimited.

Applicant type

An enterprise may apply individually or as consortium leader. Consortia may include SMEs, large enterprises, research organisations and NGOs; only an enterprise can be leader.

Application restriction

Published application period is 13 July–16 September 2026. It elapsed before this review date; current reopening/extension status is not asserted.

Eligible project scope

R&D projects under STEP Path B for critical technologies in biotechnology, including medicines on the EU critical medicines list and their components; the call thematic annex controls eligible technology scope.

Other conditionExact identified application intake only; no change to programme lifetime, implementation or evaluation stages.

The exact NCBR call is in application evaluation. Its submission intake is closed; evaluation is not a further application stage. The old ministry-portal open label is retained as source disagreement.

Operator-source status adjudication, not automatic closure from elapsed dates; no claim of live signed-in portal acceptance.

Other condition

VAT is generally ineligible, but may be eligible for an applicant or consortium member only where it has no legal right to deduct input VAT or obtain a VAT refund under applicable Polish VAT rules; the guide evaluates VAT for each consortium member. Excise and customs treatment is not established by this excerpt.

Catalogue budget

PLN 150,000,000

Figure as listed by the provider. Whether it is the total allocation or a per-project cap is unverified unless a reviewed condition says so.

Call allocation

PLN 150,000,000

Total call allocation; not a per-project amount.

Eligible cost

Eligible personnel costs cover research-scientific staff working on R&D: research employees, technical staff and auxiliary staff, employed or engaged on specified bases; remuneration is eligible only for the scope and period of R&D engagement.

Ineligible cost

Management, supervision or coordination remuneration is not eligible under the direct project-personnel category; the guide allocates such pay to indirect costs.

Project cost, minimum

PLN 10,000,000

Minimum eligible costs for a single large-enterprise project; consortium variants have separate conditions based on consortium composition.

Project cost, minimum

PLN 7,000,000

Minimum eligible costs for a single SME project; consortium variants have separate conditions based on consortium composition.

Project funding, maximum

PLN 140,000,000

Project-wide maximum; application of aid intensity and entity-specific caps can result in lower support.

• NCBR cost eligibility guide, FENG Priority 5, STEP biotechnology call

  gov.pl

• NCBR selection criteria, STEP Path B, biotechnology

  gov.pl

• NCBR current exact-call page

  gov.pl

• Official MFiPR route page: FENG 05.01-IP.01-007/26 STEP biotech

  funduszeunijne.gov.pl

• NCBR RWP, FENG.05.01-IP.01-007/26, STEP Path B biotechnology, effective 8 May 2026

  gov.pl

Opens

13 Jul 2026

Provider

FENG · NCBR

Source

funduszeunijne.gov.pl

Checked

24 Oct 2026

Review status

Partial review

Independent QA

No published hold

Reviewed

23 Oct 2026